The UK Competition Authority publishes its decision to fine a pharmaceutical company £155M for excessive pricing and £111.5M for market exclusion agreements (Auden McKenzie / Actavis)

On 31 March 2022, the CMA published one of its longest decisions (1077 pages), in which it imposed fines of £155 million on Accord-UK (previously Auden McKenzie/Actavis) for excessive price increases on hydrocortisone tablets after they were de-branded and fell outside the UK NHS price regulations. The CMA also imposed additional fines of £111.5 million for cartel agreements entered into when other parties threatened to enter the market (UK Competition and Markets Authority, Case 50277, Auden McKenzie/Actavis, 15 July 2021). An unusual aspect of the decision compared to other excessive price decisions is that Auden/Actavis received an unintended competitive advantage due to the application of the Orphan Medicines Regulation. In 2011, a separate company (Shire Pharmaceuticals – now

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Barbara Monti, Michael Clancy, David Hull, The UK Competition Authority publishes its decision to fine a pharmaceutical company £155M for excessive pricing and £111.5M for market exclusion agreements (Auden McKenzie / Actavis), 31 March 2022, e-Competitions August 2022, Art. N° 107737

Visites 43

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues